Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | RUXOPEG: a promising novel combination for MPN-associated myelofibrosis

Jean-Jacques Kiladjian • 3 Dec 2018
ASH 2018
Myelofibrosis Myeloproliferative Neoplasms Interferon Ruxolitinib
RUXOPEG

Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the RUXOPEG trial (NCT02742324) of ruxolitinib and pegylated interferon alpha 2a for myeloproliferative neoplasm-associated myelofibrosis. Prof. Kiladjian covers the initial efficacy and safety results of this novel combination from the first study to formally assess this, before explaining further plans for this regimen. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Jean-Jacques Kiladjian

16:35
Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more
Claire Harrison et al. • 11 Dec 2023
2:31
The growing role of combination approaches in MF & agents being explored
Jean-Jacques Kiladjian • 9 Oct 2023
4:35
The role of JAK2 VAF testing in risk assessment and disease monitoring in MPNs
Jean-Jacques Kiladjian • 13 Jun 2023
2:14
Ruxolitinib combinations in patients with myelofibrosis
Jean-Jacques Kiladjian • 26 Apr 2023

Related Videos

1:35
Addressing the increased risk of cardiovascular disease in patients with MPNs
Arjun Ghosh • 25 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals